DiaMedica Therapeutics to host webinar on DM199 early Phase 2 FGR results

The company said the virtual event on Oct. 23 will discuss fetal growth restriction, the rationale for DM199 and preliminary first-cohort findings from its Phase 2 early-onset FGR trial. Enrollment in the first cohort of six participants is complete and dosing has begun in the second cohort.